AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02631876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin
Description: Pegylated liposomal doxorubicin will be administered per dose and schedule specified in the arm.
Study NCT02631876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: Topotecan will be administered per dose and schedule specified in the arm.
Study NCT03204916 — intervention group
Intervention type: BEHAVIORAL
Intervention: Discussion
Description: Participate in focus group
Study NCT03204916 — intervention group
Intervention type: OTHER
Intervention: Medical Chart Review
Description: Data abstraction and central review
Study NCT03204916 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaire
Study NCT01464554 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: alcohol and drug education
Study NCT01464554 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project Free Talk
Description: motivational interviewing alcohol and drug program
Study NCT00937651 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00937651 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fimasartan (BR-A-657•K) 20 mg
Description: Fimasartan 20 mg, 1 tablet + placebo, 2 tablets
Study NCT00937651 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fimasartan (BR-A-657•K) 60 mg
Description: Fimasartan 20 mg, 1 tablet + 40 mg, 1 tablet + placebo 1 tablet
Study NCT00937651 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fimasartan (BR-A-657•K) 180 mg
Description: Fimasartan 20 mg, 1 tablet + 80 mg, 1 tablet + 80 mg 1 tablet
Study NCT02560779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carotuximab (TRC105)
Description: Bi-weekly iv TRC105 (15 mg/kg) will be given with 400mg sorafenib twice daily in the phase 1B portion of the study. Weekly iv TRC105 (10 mg/kg) will be given with 400mg sorafenib twice daily in the phase 2 portion of the study.
Study NCT02560779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: 400 mg of sorafenib will be given twice daily.
Study NCT01937247 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Patients will be inducted in the induction room
Description: The patients will be inducted in the induction room
Study NCT01937247 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Redesigned process
Description: The registered nurse will call in the house keeper to start cleaning of the OR (parallel processing) before the patient exits the room
Study NCT01937247 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: patient will be reversed with sugammadex 4mg/kg IV
Description: The patient will be reversed with sugammadex 4mg/kg IV, and then extubated before being moved out of the OR
Study NCT01937247 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: STANDARD PROCESS
Description: standard process
Study NCT00868296 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pantoprazole
Study NCT05466344 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Herbst Group
Description: 1. Two mini plates are chosen, the last hole in every plate is used to solder the ball housing of type IV Herbst appliance.~2. The two mini plates are placed bilateral at the mandibular symphysis and fixed by at least 3 screws, the surgical wound is sutured leaving an extended part of the plate in the oral cavity which contain the soldered ball housing.~3. The surgical wound is left for 2 weeks for proper soft tissue healing, in the meantime separation in the arch, band placement on the first premolar and molar bilateral followed by impression for construction of the upper Herbst splint.~4. Cementation of upper Herbst splint with connecting the telescopic piston through fitting of the plunger into the tube bilaterally.~5. When reactivation of the telescopic piston is needed, extension rings are used.
Study NCT05466344 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TFBC Group
Description: 1. The patients will be treated by fixed orthodontic appliance with using series of orthodontic NiTi arch wires for levelling and alignment.~2. Installation of series of orthodontic stainless steel arch wires until 0.0019 x 0.0025 inch for both arches.~3. Installation of the Twin Force Bite Corrector appliance for 4 to 6 months.~4. Using of class ΙΙ intra-oral elastics for both sides for 2 to 3 months.~5. Finally follow finishing steps for each patient.
Study NCT02234752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galantamine ER
Study NCT02234752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine XR
Study NCT03022669 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Message
Description: Annie (VA text messaging program) or mobile Health manager (private text messaging program for non-VA female participants recruited at non-VA facility)
Study NCT03810976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin, gemcitabine
Description: Elibulin 1.4mg/m2 Intravenous for 5minutes. Day 1\& Day 8 every 3 weeks Gemcitabine 1000mg/m2 intraveoust for 30 minutes, Day 1\& Day 8 every 3 weeks
Study NCT01658059 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Homeopathic remedy
Description: drops of the homeopathic remedy will be taken twice a day before the treatment and once on the morning of the treatment day.
Study NCT00668200 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Reclast (ZOL446, zoledronic acid)
Description: 5 mg i.v. annually (real-life, physician prescribed)
Study NCT00668200 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Calcium
Description: 1500 mg elemental calcium daily in divided doses (the divided doses were 2-3 times per day depending on the formulation)
Study NCT01658059 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: drops of the placebo will be taken twice a day before the treatment and once on the morning of the treatment day.
Study NCT04750083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HX008
Description: HX008 200 mg intravenously (IV) on Day 1 of every 3-week cycle (Q3W) for up to 35 cycles
Study NCT04750083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg intravenously (IV) on Day 1 of Q3W for up to 35 cycles
Study NCT04750083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: pemetrexed 500 mg/m\^2 IV on Day 1 of Q3W for up to 35 cycles
Study NCT04750083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin/carboplatin
Description: cisplatin 75 mg/m\^2 IV OR carboplatin AUC 5 IV on Day 1 of Q3W for 4 cycles
Study NCT04857554 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose as reference food
Description: Twelve healthy, normal weight subjects (male: 6,female: 6) after 10-14 hr fast, consumed 25g glucose diluted in 250ml water, tested twice, in different weeks, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45,60, 90 and 120min.
Study NCT04857554 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White bread as reference food
Description: Twelve healthy, normal weight subjects (male: 6,female: 6) after 10-14 hr fast, consumed 25g available carbohydrates from white bread along with 250ml water, tested once, in different weeks, within 10-15min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45,60, 90 and 120min.
Study NCT04857554 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White bread with apricot jam
Description: Twelve healthy, normal weight subjects (male: 6,female: 6) after 10-14 hr fast, consumed 25g available carbohydrates from white bread together with apricot jam along with 250ml water, tested once, in different weeks, within 10-15min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45,60, 90 and 120min.
Study NCT04857554 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cereal bar with cranberries
Description: Twelve healthy, normal weight subjects (male: 6,female: 6) after 10-14 hr fast, consumed 25g available carbohydrates from a cereal bar with cranberries along with 250ml water, tested once, in different weeks, within 10-15min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45,60, 90 and 120min.
Study NCT04857554 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cocoa drink
Description: Twelve healthy, normal weight subjects (male: 6,female: 6) after 10-14 hr fast, consumed 25g available carbohydrates from cocoa powder mixed with 500ml fat-free milk, tested once, in different weeks, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45,60, 90 and 120min.
Study NCT02001246 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Real Deal program for Anger Management
Description: Real Deal is an eight week program with sessions one day per week. Each session is approximately 2 hr long.
Study NCT02001246 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind-body Bridging (MBB) program
Description: MBB is an eight week program with sessions one day per week. Each session is approximately 2 hr long.
Study NCT06324032 — intervention group
Intervention type: PROCEDURE
Intervention: EUS Elastography (EUS-E)
Description: All procedures will be performed with Olympus echoendoscopes (Olympus Europa SE \& CO. KG, Hamburg, Germany) or Pentax echoendoscopes in combination with dedicated elastography software
Study NCT00285779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: etanercept 50 mg twice weekly for 12 weeks
Study NCT00285779 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01065220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testolactone undecanoate
Description: 4ml i.m.
Study NCT01065220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lynestrenol
Description: 2/day
Study NCT01065220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyproterone Acetate
Description: 50mg per day
Study NCT01065220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol
Description: 100 microgram TTS twice a week
Study NCT01065220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-alpha reductase inhibitor
Description: 1mg daily
Study NCT01283750 — intervention group
Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: care coordination
Description: dementia-related care coordination
Study NCT01317719 — intervention group
Intervention type: PROCEDURE
Intervention: Distal Biceps Re-Insertion Surgery
Description: Surgical Repair of the Distal Biceps Tendon
Study NCT03520413 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PRACTICE-DM
Description: Five-component diabetes intervention: 1) telemonitoring; 2) self-management support; 3) diet/activity support; 4) medication management; and 5) depression support.
Study NCT01678521 — intervention group
Intervention type: PROCEDURE
Intervention: LDL-apheresis
Description: The acronym H.E.L.P. stands for Heparin-induced Extracorporeal Low-density-lipoprotein Precipitation. Antecubital veins served as blood access. The mean blood volume processed per session is of approximately 3000 ml.
Study NCT00730886 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ExAblate 2000
Description: Magnetic resonance image guided focused ultrasound (MRgFUS) for fibroid ablation
Study NCT00730886 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Myomectomy
Description: Invasive surgical procedure for fibroid removal
Study NCT04268914 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oculus Go VR
Description: The Oculus Go is a standalone headset with built-in speakers that runs independently of a smartphone. Via the Oculus Go, participants will engage with BearBlast (developed by AppliedVR). Throughout the world, plush moles play the role of antagonist, standing in for the nuisance and distraction of pain. The VR game is equipped with a head-tracking system, enabling the player to look around the virtual environment. In addition, there is the option to interact with the VR environment using a tap pad located on the side of the helmet. Therefore, the child will be receiving distraction via 3-D visual and auditory sensory, and tactile feedback, thus supplying a multi-sensory immersive experience. The VR HMD runs independently of a smartphone and has active matrix LCDs with high pixel resolution, creating a bright, vibrant color and a quality image.
Study NCT04268914 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mira Prism VR
Description: The Mira Prism is a portable, augmented reality (AR) HMD powered by iPhone. When paired with the iPhone, the Mira Prism goggles can superimpose computer-generated images on the user's view of the real world. Unlike the full immersion of VR, AR allows users to view the outside world while interacting with digital content. In this study, the patient will interact with Magic Mallet (developed by Miney Moe) until falling asleep during the anesthesia induction process. Magic Mallet is a distraction game designed for pain management and communication during procedures. The game automatically adjusts cognitive load for optimal effect for users. Study team iPhones specifically loaded with Magic Mallet, and without cellular capability, will be used with the Mira Prism.
Study NCT00484263 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hypertonic saline 6% -
Description: Hypertonic saline (6%) - 5mls twice a day via a nebuliser for 12 months
Study NCT01591629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone
Description: Active Naloxone 18 mcg/kg intravenously over 60 minutes, 2mg IV push, 1mg IV push
Study NCT01591629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delta-9-THC
Description: Active Delta-9-THC (0.025mg/Kg) given intravenously over 20 minutes.
Study NCT00668200 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Vitamin D
Description: 800 IU vitamin D daily, particularly in the immediate 2 weeks following zoledronic acid administration
Study NCT00844649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin-bound paclitaxel (ABI-007)
Description: ABI-007 125 mg/m\^2 administered by intravenous infusion
Study NCT00844649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine, 1000 mg/m2 administered weekly for 7 weeks, Day 1 through Day 43 followed by a week of rest (Cycle 1), followed by cycles of weekly administration for 3 weeks, Days 1, 8, and 15 followed by a week of rest (Cycle 2 onward).
Study NCT00844649 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine, 1000 mg/m2 administered weekly for 7 weeks, Day 1 through Day 43 followed by a week of rest (Cycle 1), followed by cycles of weekly administration for 3 weeks, Days 1, 8, and 15 followed by a week of rest (Cycle 2 onward).
Study NCT01591629 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Delta-9-THC
Description: Active Delta-9-THC (0.025mg/Kg) given intravenously over 20 minutes.
Study NCT01591629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT01591629 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01346124 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: High Dose Intensity Modulated Proton Radiation
Description: Radiation given once a day Monday-Friday
Study NCT02935764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 180 mg/m2 iv gtt, d1
Study NCT02935764 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: 180 mg/m2 iv gtt, d1
Study NCT02935764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: 5-FU 400mg/m2 iv, 2400mg/m2 civ 46h
Study NCT02935764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: 400mg/m2 iv gtt,d1
Study NCT03478605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Olanzapine 5 mg/day will be administered orally on days 0-4 of chemotherapy cycle (before bedtime)
Study NCT03478605 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aprepitant Pill
Description: Aprepitant 125 mg orally will be administered on day 1 of chemotherapy cycle; 80 mg - on days 2 and 3.
Study NCT03520413 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard VA Home Telehealth
Description: Standard VA HT care coordination and telemonitoring.
Study NCT03478605 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: Ondansetron 16 mg IV on day 1 of chemotherapy cycle (as standard component of antiemetic therapy)
Study NCT03478605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Ondansetron 16 mg IV on day 1 of chemotherapy cycle (as standard component of antiemetic therapy)
Study NCT03478605 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone 8 mg IV on day 1 of chemotherapy cycle; 8 mg IV or orally on days 2-3 (as standard component of antiemetic therapy)
Study NCT03478605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 8 mg IV on day 1 of chemotherapy cycle; 8 mg IV or orally on days 2-3 (as standard component of antiemetic therapy)
Study NCT04735341 — intervention group
Intervention type: DEVICE
Intervention: Ion Endoluminal System
Description: Ion Endoluminal Procedure for pulmonary nodule
Study NCT03304964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FP-025 (MMP-12 inhibitor)
Description: Treatment A: 14 oral doses of 100 mg FP-025 (n=6) or placebo (n=2) in 8 days.
Study NCT03304964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FP-025 (MMP-12 inhibitor)
Description: Treatment B: 14 oral doses of 200 mg FP-025 (n=6) or placebo (n=2) in 8 days.
Study NCT03304964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FP-025 (MMP-12 inhibitor)
Description: Treatment C: 14 oral doses of 400 mg FP-025 (n=6) or placebo (n=2) in 8 days.
Study NCT03304964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FP-025 (MMP-12 inhibitor)
Description: Treatment D: single oral dose of 200 mg FP-025 under fasted conditions.
Study NCT04558424 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: zinc gluconate and ascorbic acid
Description: This group will consist of 50 patients who will receive 220 mg zinc and 1gm ascorbic acid for 10 days in addition to their standard treatment.
Study NCT04558424 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: zinc gluconate and ascorbic acid
Description: This group will consist of 50 patients who will receive 220 mg zinc and 1gm ascorbic acid for 10 days in addition to their standard treatment.
Study NCT03590080 — intervention group
Intervention type: DRUG
Intervention: Methylprednisolone
Study NCT01681251 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluid titrated with the use of arterial pulse contour cardiac output monitor if SVV >13%
Description: Following induction of anesthesia, Voluven boluses of 250ml will be given if SVV increases above 10%. Further Voluven boluses will be given in 250ml aliquots should the SVV increase to greater than 10%. If a total of 55ml/kg of Voluven is given, the fluid will be changed to lactated ringers and no further colloid will be given, as this is the maximum dose recommend by the manufacturer.~Vasoactive agents (type and dose at the discretion of the attending anesthesiologist) may be given to maintain a mean arterial pressure that the clinical team feels adequate to maintain adequate organ perfusion. In the intervention group, however, vasoactive agents will not be given unless fluid administration has resulted in a maximal value of SV.
Study NCT01681251 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fluid titrated at the discretion of the attending anesthesiologist
Description: In the control group, the data from the FloTrac monitor will not be available to the anesthesia care provider. Fluid replacement will be at a rate and of a type that is entirely up to the anesthesiologist; the only stipulation being that Voluven is to be used should the provider desire to use a colloid solution.
Study NCT01422616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-dose rtPA
Description: Patients allocated to low-dose will receive 0.6 mg/kg (maximum of 60 mg) i.v. (15% bolus \[maximum bolus dose of 9mg\] and 85% infusion over 60 mins) recombinant tissue plasminogen activator (rtPA).
Study NCT01422616 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard-dose rtPA
Description: Patients allocated to standard-dose will receive 0.9 mg/kg (maximum of 90 mg) i.v. (10% bolus and 90% infusion over 60 mins) rtPA.
Study NCT01422616 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure (BP) lowering
Description: Intensive blood pressure (BP) lowering to a target systolic BP range 130-140 mmHg within one hour and to maintain this level for at least 72 hours (or until hospital discharge or death if this should occur earlier). A standardised i.v. BP lowering regimen using locally available and approved i.v. BP lowering agents will be used, commenced in the emergency department and later in a high dependency area (e.g. acute stroke or neurointensive care unit) as is usual for patients receiving rtPA.~The trial is an assessment of BP lowering management strategies, using routinely available drugs. There is some flexibility in the use of particular BP lowering agents to achieve BP targets.